Plasma Concentrations of the Enantiomers of Fluoxetine and Norfluoxetine: Sources of Variability and Preliminary Observations on Relations With Clinical Response
暂无分享,去创建一个
P. Magni | E. Perucca | E. Spina | R. Pacifici | P. Zuccaro | G. Gatti | G. Jannuzzi | L. Guarneri | Riccardo Torta
[1] N H Holford,et al. Target concentration intervention: beyond Y2K. , 2001, British journal of clinical pharmacology.
[2] H. Zhou,et al. Effect of the CYP2C19 oxidation polymorphism on fluoxetine metabolism in Chinese healthy subjects. , 2001, British journal of clinical pharmacology.
[3] S. Binkley,et al. Identification of the human cytochromes p450 responsible for in vitro formation of R- and S-norfluoxetine. , 2001, The Journal of pharmacology and experimental therapeutics.
[4] C. Eap,et al. Concentrations of the Enantiomers of Fluoxetine and Norfluoxetine After Multiple Doses of Fluoxetine in Cytochrome P4502D6 Poor and Extensive Metabolizers , 2001, Journal of clinical psychopharmacology.
[5] M. Reis,et al. Serum Concentrations of Fluoxetine in the Clinical Treatment Setting , 2001, Therapeutic drug monitoring.
[6] S. Ekins,et al. (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[7] K. Brøsen,et al. The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine. , 1999, Pharmacogenetics.
[8] E. Perucca,et al. Issues in methodology and applications for therapeutic drug monitoring of fluoxetine and norfluoxetine enantiomers. , 1998, Therapeutic drug monitoring.
[9] A. Holtz,et al. Fluoxetine tenth anniversary update: the progress continues. , 1997, Clinical therapeutics.
[10] D. Greenblatt,et al. Human cytochromes mediating N-demethylation of fluoxetine in vitro , 1997, Psychopharmacology.
[11] J. Amsterdam,et al. Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study. , 1997, The American journal of psychiatry.
[12] S. Oparil. The expanding role of calcium antagonists in cardiovascular disease , 1997 .
[13] R. Pacifici,et al. Stereoselective determination of fluoxetine and norfluoxetine enantiomers in plasma samples by high-performance liquid chromatography , 1996 .
[14] W. Burke,et al. Fluoxetine and norfluoxetine serum concentrations and clinical response in weekly versus daily dosing. , 1996, Psychopharmacology bulletin.
[15] L. Balant,et al. Therapeutic Drug Monitoring , 1995 .
[16] J. Lieberman,et al. Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. , 1995, The American journal of psychiatry.
[17] L. Endrenyi,et al. Comparative efficiencies of randomized concentration‐ and dose‐controlled clinical trials , 1994, Clinical pharmacology and therapeutics.
[18] A. Altamura,et al. Clinical Pharmacokinetics of Fluoxetine , 1994, Clinical pharmacokinetics.
[19] L. Gram. Drug therapy : fluoxetine , 1994 .
[20] S. Wrighton,et al. Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochromes P450. , 1993, The Journal of pharmacology and experimental therapeutics.
[21] D. Wong,et al. Norfluoxetine Enantiomers as Inhibitors of Serotonin Uptake in Rat Brain , 1993, Neuropsychopharmacology.
[22] R. Fuller,et al. Comparison of norfluoxetine enantiomers as serotonin uptake inhibitors in vivo , 1992, Neuropharmacology.
[23] G. Baker,et al. Simultaneous determination of fluoxetine and norfluoxetine enantiomers in biological samples by gas chromatography with electron-capture detection. , 1992, Journal of chromatography.
[24] R. Cadoret,et al. Dr. Perry and Associates Reply , 1991 .
[25] D. Murphy,et al. Sustained plasma concentrations of fluoxetine and/or norfluoxetine four and eight weeks after fluoxetine discontinuation. , 1991, Journal of clinical psychopharmacology.
[26] R. Cadoret,et al. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. , 1991, The American journal of psychiatry.
[27] S. Sclove. Application of model-selection criteria to some problems in multivariate analysis , 1987 .
[28] J. Cohn,et al. Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder. , 1985, The Journal of clinical psychiatry.
[29] D. Wong,et al. Inhibition of serotonin uptake by optical isomers of fluoxetine , 1985 .
[30] D. Kleinbaum,et al. Applied Regression Analysis and Other Multivariate Methods , 1978 .
[31] H. Akaike. A new look at the statistical model identification , 1974 .